Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (13)

2024

  1. Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835

2022

  1. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427

  2. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

    ESMO Open, Vol. 7, Núm. 2

  3. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311

  4. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

    JTO Clinical and Research Reports, Vol. 3, Núm. 6

  5. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

    ESMO Open, Vol. 7, Núm. 2

2021

  1. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65

  2. First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

    International Journal of Clinical Oncology, Vol. 26, Núm. 6, pp. 1073-1082

  3. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

  4. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

    Future Oncology, Vol. 17, Núm. 10, pp. 1165-1184

2018

  1. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536

2017

  1. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

    New England Journal of Medicine, Vol. 377, Núm. 20, pp. 1919-1929

2010

  1. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 6, pp. 2664-2671